Recently, the 2025 winners of the International Design Excellence Awards (IDEA), one of the world’s top three design awards, were officially announced. WBL LIPUS from WBL stood out and successfully won this prestigious international design honor. As a pioneer in LIPUS technology, WBL was the first to apply this technology in the treatment of erectile dysfunction (ED). This award not only marks a significant breakthrough in Chinese original medical technology within the international design field, but also confirms its leading position in the industry.
The IDEA, organized by the Industrial Designers Society of America (IDSA), is one of the most influential design awards globally. Its core mission is to recognize works that set benchmarks in product innovation, functional design, and the integration of social value. The evaluation criteria emphasize a deep combination of technological breakthroughs and human-centered design, as well as the positive impact on society. WBL LIPUS’s receipt of the IDEA Design Award is an authoritative acknowledgment of its perfect fusion of these two aspects.
The creation of WBL LIPUS originated from the male sexual dysfunction rehabilitation engineering design by Chinese Academy of Engineering Academician Guo Yinglu and Professor Lv Futai from the University of California, San Francisco. As a non-invasive physical therapy device, its core function is to apply specific frequency pulse ultrasound precisely to the target tissue of the human body, converting mechanical force into biological effects. This regulates cell signaling pathways to promote vascular regeneration, repair nerve damage, and inhibit inflammatory responses, fundamentally repairing pathological changes in the penile corpus cavernosum. This mechanism is closely related to the activation of endogenous stem cells. Compared with traditional ED treatments and regenerative therapies, LIPUS is a proven non-invasive method that effectively promotes nerve and vascular regeneration, filling a technological gap both domestically and internationally.
To verify its efficacy and safety, the technology underwent biological mechanism research led by Professors Xin Zhongcheng and Lin Guiting, as well as clinical trials conducted by multiple hospitals. The results confirmed that its treatment success rate for mild to moderate ED exceeded 71%, with no drug side effects. With solid research achievements, the device first received approval from the China Food and Drug Administration (CFDA) for market launch, and later won the China National Medical Device Innovation Award, forming a complete closed loop from clinical validation to authoritative recognition.
As an industry pioneer, WBL has established its leadership in non-invasive treatment by providing ED patients with a safe and efficient new treatment option, while also building a comprehensive theoretical and practical system from basic research to clinical application.
In the future, WBL will continue to deepen its focus on micro-energy medicine, expand its range of indications, and integrate AI technology to develop personalized solutions, providing more efficient and safe medical solutions for patients worldwide.
